# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001764013-24-000116
Filing Date
2024-06-26
Accepted
2024-06-26 07:01:21
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | defa14aadditionalmaterials.htm | DEFA14A | 13708
2 | GRAPHIC | immunovantinc_vxnaxp14830xb.jpg | GRAPHIC | 489229
3 | GRAPHIC | immunovantinc_vxnaxp14830xc.jpg | GRAPHIC | 387582
| Complete submission text file | 0001764013-24-000116.txt |  | 1222101

Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: DEFA14A | Act: 34 | File No.: 001-38906 | Film No.: 241070600
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)